Literature DB >> 22334493

Hepatobiliary MR imaging with gadolinium-based contrast agents.

Alex Frydrychowicz1, Meghan G Lubner, Jeffrey J Brown, Elmar M Merkle, Scott K Nagle, Neil M Rofsky, Scott B Reeder.   

Abstract

The advent of gadolinium-based "hepatobiliary" contrast agents offers new opportunities for diagnostic magnetic resonance imaging (MRI) and has triggered great interest for innovative imaging approaches to the liver and bile ducts. In this review article we discuss the imaging properties of the two gadolinium-based hepatobiliary contrast agents currently available in the U.S., gadobenate dimeglumine and gadoxetic acid, as well as important pharmacokinetic differences that affect their diagnostic performance. We review potential applications, protocol optimization strategies, as well as diagnostic pitfalls. A variety of illustrative case examples will be used to demonstrate the role of these agents in detection and characterization of liver lesions as well as for imaging the biliary system. Changes in MR protocols geared toward optimizing workflow and imaging quality are also discussed. It is our aim that the information provided in this article will facilitate the optimal utilization of these agents and will stimulate the reader's pursuit of new applications for future benefit.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22334493      PMCID: PMC3281562          DOI: 10.1002/jmri.22833

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  108 in total

1.  Cavernous hemangioma of the liver.

Authors:  J L OCHSNER; B HALPERT
Journal:  Surgery       Date:  1958-04       Impact factor: 3.982

2.  Hemangioma of the liver; special reference to its association with cysts of the liver and pancreas.

Authors:  M FELDMAN
Journal:  Am J Clin Pathol       Date:  1958-02       Impact factor: 2.493

Review 3.  Functional MR cholangiography: diagnosis of functional abnormalities of the gallbladder and biliary tree.

Authors:  Laura M Fayad; Ihab R Kamel; Donald G Mitchell; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2005-05       Impact factor: 3.959

4.  Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

Authors:  Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2005-11       Impact factor: 6.016

5.  Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations.

Authors:  Alexander Huppertz; Sibylle Haraida; Armin Kraus; Christoph J Zech; Juergen Scheidler; Josy Breuer; Thomas K Helmberger; Maximilian F Reiser
Journal:  Radiology       Date:  2004-12-10       Impact factor: 11.105

6.  Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.

Authors:  Luigi Grazioli; Giovanni Morana; Miles A Kirchin; Günther Schneider
Journal:  Radiology       Date:  2005-06-13       Impact factor: 11.105

7.  Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver.

Authors:  Sara Vander Borght; Louis Libbrecht; Hans Blokzijl; Klaas Nico Faber; Han Moshage; Raymond Aerts; Werner Van Steenbergen; Peter L Jansen; Valeer J Desmet; Tania A Roskams
Journal:  J Pathol       Date:  2005-12       Impact factor: 7.996

8.  Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.

Authors:  Dushyant V Sahani; Sanjeeva P Kalva; Alan J Fischman; Rajagopal Kadavigere; Michael Blake; Peter F Hahn; Sanjay Saini
Journal:  AJR Am J Roentgenol       Date:  2005-07       Impact factor: 3.959

9.  Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.

Authors:  David A Bluemke; Dushyant Sahani; Marco Amendola; Thomas Balzer; Josy Breuer; Jeffrey J Brown; David D Casalino; Peter L Davis; Isaac R Francis; Glenn Krinsky; Fred T Lee; David Lu; Erik K Paulson; Lawrence H Schwartz; Evan S Siegelman; William C Small; Therese M Weber; Adam Welber; Kohkan Shamsi
Journal:  Radiology       Date:  2005-08-26       Impact factor: 11.105

10.  Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.

Authors:  Kazuhiro Saito; Fumio Kotake; Naoki Ito; Taizo Ozuki; Ryuji Mikami; Kimihiko Abe; Yoko Shimazaki
Journal:  Magn Reson Med Sci       Date:  2005       Impact factor: 2.471

View more
  45 in total

1.  High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

Authors:  Scott K Nagle; Reed F Busse; Anja C Brau; Jean H Brittain; Alex Frydrychowicz; Yuji Iwadate; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-05-30       Impact factor: 4.813

Review 2.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

3.  Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?

Authors:  Kumar Sandrasegaran; Enming Cui; Reem Elkady; Pauley Gasparis; Gitasree Borthakur; Mark Tann; Suthat Liangpunsakul
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

Review 4.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

Review 5.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

Review 6.  MRI evaluation of bile duct injuries and other post-cholecystectomy complications.

Authors:  Shilpa Reddy; Camila Lopes Vendrami; Pardeep Mittal; Amir A Borhani; Courtney C Moreno; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2021-02-12

7.  Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.

Authors:  Matteo Bonatti; Riccardo Valletta; Giulia A Zamboni; Fabio Lombardo; Maria Senoner; Mariachiara Simioni; Guenther Schifferle; Giampietro Bonatti
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

8.  Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.

Authors:  Massimo Galia; Francesco Agnello; Gianvincenzo Sparacia; Domenica Matranga; Domenico Albano; Massimo Midiri; Roberto Lagalla
Journal:  Radiol Med       Date:  2018-03-15       Impact factor: 3.469

9.  Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs.

Authors:  Christopher G Roth; Dina Halegoua-De Marzio; Flavius F Guglielmo
Journal:  Dig Dis Sci       Date:  2018-05       Impact factor: 3.199

10.  Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.

Authors:  Elsa Iannicelli; Marco Di Pietropaolo; Massimo Marignani; Chiara Briani; Giulia Francesca Federici; Gianfranco Delle Fave; Vincenzo David
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.